百克生物
(688276)
| 流通市值：92.41亿 | | | 总市值：92.41亿 |
| 流通股本：4.14亿 | | | 总股本：4.14亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 246,759,293.74 | 224,103,669.86 | 344,869,136.24 | 277,889,806.27 |
| 应收票据及应收账款 | 1,176,692,608.36 | 1,365,404,497.99 | 1,406,666,599.33 | 1,670,819,275.87 |
| 其中：应收票据 | - | 1,000,000 | 1,000,000 | 4,601,029.6 |
| 应收账款 | 1,176,692,608.36 | 1,364,404,497.99 | 1,405,666,599.33 | 1,666,218,246.27 |
| 预付款项 | 44,095,018.41 | 44,038,447.73 | 25,052,996.52 | 24,711,550.55 |
| 其他应收款合计 | 1,910,253.33 | 2,085,049.76 | 2,085,214.99 | 1,764,268.62 |
| 存货 | 278,753,114 | 211,195,454.4 | 170,776,028.1 | 197,269,757.66 |
| 其他流动资产 | 32,863,553.84 | 19,508,696.72 | 15,185,752.73 | 2,104,999.29 |
| 流动资产合计 | 1,781,073,841.68 | 1,866,335,816.46 | 1,964,635,727.91 | 2,174,559,658.26 |
| 非流动资产: | | | | |
| 长期股权投资 | 368,508,767.8 | 376,759,689.87 | 33,482,864.39 | 33,774,392.1 |
| 其他权益工具投资 | 20,630,607.33 | 22,838,486.82 | 177,856,876.94 | 150,771,556.02 |
| 固定资产 | 1,051,917,994.1 | 1,078,042,207.87 | 1,091,386,926.74 | 1,005,106,372.62 |
| 在建工程 | 1,495,505,460.53 | 1,461,383,150.11 | 1,386,382,013.65 | 1,341,859,286.8 |
| 无形资产 | 300,358,523.26 | 319,230,398.57 | 330,604,460.81 | 332,576,936.5 |
| 开发支出 | 5,033,579.69 | - | - | - |
| 长期待摊费用 | 66,768,347.13 | 71,830,216.8 | 74,675,730.9 | 22,911,507.03 |
| 递延所得税资产 | 119,425,642.69 | 101,553,253.6 | 96,281,759.54 | 124,859,219.79 |
| 其他非流动资产 | 55,464,508.54 | 54,213,660.08 | 49,562,476.67 | 127,537,828.28 |
| 非流动资产合计 | 3,483,613,431.07 | 3,485,851,063.72 | 3,240,233,109.64 | 3,139,397,099.14 |
| 资产总计 | 5,264,687,272.75 | 5,352,186,880.18 | 5,204,868,837.55 | 5,313,956,757.4 |
| 流动负债: | | | | |
| 短期借款 | 155,537,203.6 | 93,159,949.11 | 42,898,918.01 | 25,809,437.97 |
| 应付票据及应付账款 | 27,797,150.37 | 18,382,260.79 | 13,810,261.48 | 13,750,406.57 |
| 其中：应付票据 | - | 87,735 | 87,735 | - |
| 应付账款 | 27,797,150.37 | 18,294,525.79 | 13,722,526.48 | 13,750,406.57 |
| 合同负债 | 1,027,119.76 | 970,005.83 | 2,201,325.54 | 2,305,893.54 |
| 应付职工薪酬 | 28,214,009.54 | 19,625,459.73 | 28,072,774.39 | 49,372,720.78 |
| 应交税费 | 973,461.04 | 2,731,369.97 | 6,620,709.11 | 56,943,553.15 |
| 其他应付款合计 | 852,984,435.89 | 871,388,544.46 | 752,690,595.85 | 814,999,352.94 |
| 其他流动负债 | 9,469,024.85 | 38,856,873.8 | 70,771,900.07 | 103,599,626.01 |
| 流动负债合计 | 1,076,002,405.05 | 1,045,114,463.69 | 917,066,484.45 | 1,066,780,990.96 |
| 非流动负债: | | | | |
| 长期借款 | 107,844,630.08 | 82,061,861.15 | 59,929,861.15 | 36,773,101.1 |
| 预计负债 | 259,734.26 | 259,734.26 | 242,631.83 | 356,941.44 |
| 递延收益 | 8,436,692.08 | 8,724,182.21 | 9,000,358.34 | 9,063,636.33 |
| 递延所得税负债 | 831,324.3 | 856,278.04 | 881,231.79 | 906,185.55 |
| 非流动负债合计 | 117,372,380.72 | 91,902,055.66 | 70,054,083.11 | 47,099,864.42 |
| 负债合计 | 1,193,374,785.77 | 1,137,016,519.35 | 987,120,567.56 | 1,113,880,855.38 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 413,657,598 | 413,657,598 | 413,657,598 | 413,657,598 |
| 资本公积 | 1,843,967,146.68 | 1,841,402,483.3 | 1,840,287,470.97 | 1,837,697,004.37 |
| 其他综合收益 | -31,763,983.79 | -29,887,286.22 | -25,268,180.14 | -52,626,075.2 |
| 盈余公积 | 533,475,182 | 533,475,182 | 533,502,800.24 | 486,349,744.2 |
| 未分配利润 | 1,311,976,544.09 | 1,456,522,383.75 | 1,455,568,580.92 | 1,514,997,630.65 |
| 归属于母公司股东权益合计 | 4,071,312,486.98 | 4,215,170,360.83 | 4,217,748,269.99 | 4,200,075,902.02 |
| 股东权益合计 | 4,071,312,486.98 | 4,215,170,360.83 | 4,217,748,269.99 | 4,200,075,902.02 |
| 负债和股东权益合计 | 5,264,687,272.75 | 5,352,186,880.18 | 5,204,868,837.55 | 5,313,956,757.4 |
| 公告日期 | 2025-08-30 | 2025-04-21 | 2025-04-21 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |